Updates on Molecular and Biochemical Development and Progression of Prostate Cancer
Prostate cancer (PCa) represents the most commonly non-cutaneous diagnosed cancer in men worldwide and occupies a very wide area of preclinical and clinical research. Targeted therapy for any cancer depends on the understanding of the molecular bases and natural behaviour of the diseases. Despite th...
Guardado en:
Autores principales: | Omar Fahmy, Nabil A. Alhakamy, Waleed Y. Rizg, Alaa Bagalagel, Abdulmohsin J. Alamoudi, Hibah M. Aldawsari, Aiah M. Khateb, Basmah M. Eldakhakhny, Usama A. Fahmy, Wesam H. Abdulaal, Claudia G. Fresta, Giuseppe Caruso |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/76be595143794623a324bb2edae60e12 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn UW, et al.
Publicado: (2013) -
Synthesis of magnetic molecularly imprinted polymers with excellent biocompatibility for the selective separation and inhibition of testosterone in prostate cancer cells
por: Tang X, et al.
Publicado: (2017) -
Association between Helicobacter pylori infection and mortality risk in prostate cancer patients receiving androgen deprivation therapy: A real‐world evidence study
por: Jui‐Ming Liu, et al.
Publicado: (2021) -
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Karen A. Autio, et al.
Publicado: (2021) -
Post-Operative Radiotherapy in Prostate Cancer: Is It Time for a Belt and Braces Approach?
por: Nicolas Giraud, et al.
Publicado: (2021)